A.forall has acquired four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm’s US portfolio.
This acquisition is a key milestone in the company’s renewed focus. A.forall considerably extends its marketed portfolio in the US, marking a significant expansion of its US footprint
With a dedicated team on the ground and an ambition to grow further, A.forall reaffirms its commitment to high-quality generics in the US.
🔗 Read the full press release
📽️ Watch the video message from CEO Steen Vangsgaard below.